Literature DB >> 12770562

Comparative analysis of fatty acid amide hydrolase and cb(1) cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling.

M Egertová1, B F Cravatt, M R Elphick.   

Abstract

Fatty acid amide hydrolase (FAAH) catalyses hydrolysis of the endocannabinoid arachidonoylethanolamide ("anandamide") in vitro and regulates anandamide levels in the brain. In the cerebellar cortex, hippocampus and neocortex of the rat brain, FAAH is located in the somata and dendrites of neurons that are postsynaptic to axon fibers expressing the CB(1) cannabinoid receptor [Proc R Soc Lond B 265 (1998) 2081]. This complementary pattern of FAAH and CB(1) expression provided the basis for a hypothesis that endocannabinoids may function as retrograde signaling molecules at synapses in the brain [Proc R Soc Lond B 265 (1998) 2081; Phil Trans R Soc Lond 356 (2001) 381] and subsequent experimental studies have confirmed this [Science 296 (2002) 678]. To assess more widely the functions of FAAH in the brain and the potential impact of FAAH activity on the spatiotemporal dynamics of endocannabinoid signaling in different regions of the brain, here we have employed immunocytochemistry to compare the distribution of FAAH and CB(1) throughout the mouse brain, using FAAH(-/-) mice as negative controls to validate the specificity of FAAH-immunoreactivity observed in wild type animals. In many regions of the brain, a complementary pattern of FAAH and CB(1) expression was observed, with FAAH-immunoreactive neuronal somata and dendrites surrounded by CB(1)-immunoreactive fibers. In these regions of the brain, FAAH may regulate postsynaptic formation of anandamide, thereby influencing the spatiotemporal dynamics of retrograde endocannabinoid signaling. However, in some regions of the brain such as the globus pallidus and substantia nigra pars reticulata, CB(1) receptors are abundant but with little or no associated FAAH expression and in these brain regions the spatial impact and/or duration of endocannabinoid signaling may be less restricted than in regions enriched with FAAH. A more complex situation arises in several regions of the brain where both FAAH and CB(1) are expressed but in a non-complementary pattern, with FAAH located in neurons and/or oligodendrocytes that are proximal but not postsynaptic to CB(1)-expressing axon fibers. Here FAAH may nevertheless influence endocannabinoid signaling but more remotely. Finally, there are regions of the brain where FAAH-immunoreactive neurons and/or oligodendrocytes occur in the absence of CB(1)-immunoreactive fibers and here FAAH may be involved in regulation of signaling mediated by other endocannabinoid receptors or by receptors for other fatty acid amide signaling molecules. In conclusion, by comparing the distribution of FAAH and CB(1) in the mouse brain, we have provided a neuroanatomical framework for comparative analysis of the role of FAAH in regulation of the spatiotemporal dynamics of retrograde endocannabinoid signaling in different regions of the brain.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12770562     DOI: 10.1016/s0306-4522(03)00145-3

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  110 in total

1.  Modulation of anticonvulsant effects of cannabinoid compounds by GABA-A receptor agonist in acute pentylenetetrazole model of seizure in rat.

Authors:  Nima Naderi; Leila Ahmad-Molaei; Farzad Aziz Ahari; Fereshteh Motamedi
Journal:  Neurochem Res       Date:  2011-04-23       Impact factor: 3.996

Review 2.  Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease.

Authors:  Celina S Liu; Sarah A Chau; Myuri Ruthirakuhan; Krista L Lanctôt; Nathan Herrmann
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

3.  Equipotent inhibition of fatty acid amide hydrolase and monoacylglycerol lipase - dual targets of the endocannabinoid system to protect against seizure pathology.

Authors:  Vinogran Naidoo; David A Karanian; Subramanian K Vadivel; Johnathan R Locklear; JodiAnne T Wood; Mahmoud Nasr; Pamela Marie P Quizon; Emily E Graves; Vidyanand Shukla; Alexandros Makriyannis; Ben A Bahr
Journal:  Neurotherapeutics       Date:  2012-10       Impact factor: 7.620

4.  The wake-promoting peptide orexin-B inhibits glutamatergic transmission to dorsal raphe nucleus serotonin neurons through retrograde endocannabinoid signaling.

Authors:  Samir Haj-Dahmane; Roh-Yu Shen
Journal:  J Neurosci       Date:  2005-01-26       Impact factor: 6.167

5.  Endocannabinoids and their implications for epilepsy.

Authors:  Bradley E Alger
Journal:  Epilepsy Curr       Date:  2004 Sep-Oct       Impact factor: 7.500

Review 6.  Paracetamol: new vistas of an old drug.

Authors:  Alfio Bertolini; Anna Ferrari; Alessandra Ottani; Simona Guerzoni; Raffaella Tacchi; Sheila Leone
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

7.  The endocannabinoid 2-arachidonoylglycerol is responsible for the slow self-inhibition in neocortical interneurons.

Authors:  Silvia Marinelli; Simone Pacioni; Tiziana Bisogno; Vincenzo Di Marzo; David A Prince; John R Huguenard; Alberto Bacci
Journal:  J Neurosci       Date:  2008-12-10       Impact factor: 6.167

8.  Rational design of fatty acid amide hydrolase inhibitors that act by covalently bonding to two active site residues.

Authors:  Katerina Otrubova; Monica Brown; Michael S McCormick; Gye W Han; Scott T O'Neal; Benjamin F Cravatt; Raymond C Stevens; Aron H Lichtman; Dale L Boger
Journal:  J Am Chem Soc       Date:  2013-04-12       Impact factor: 15.419

9.  Obesity-related dyslipidemia associated with FAAH, independent of insulin response, in multigenerational families of Northern European descent.

Authors:  Yi Zhang; Gabriele E Sonnenberg; Tesfaye Mersha Baye; Jack Littrell; Jennifer Gunnell; Ann DeLaForest; Erin MacKinney; Cecilia J Hillard; Ahmed H Kissebah; Michael Olivier; Russell A Wilke
Journal:  Pharmacogenomics       Date:  2009-12       Impact factor: 2.533

10.  Endocannabinoid signaling in neurotoxicity and neuroprotection.

Authors:  C Pope; R Mechoulam; L Parsons
Journal:  Neurotoxicology       Date:  2009-12-05       Impact factor: 4.294

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.